Hitting multiple targets with multimeric ligands

Multimeric ligands consist of multiple monomeric ligands attached to a single backbone molecule, creating a multimer that can bind to multiple receptors or targets simultaneously. Numerous examples of multimeric binding exist within nature. Due to the multiple and simultaneous binding events, multimeric ligands bind with an increased affinity compared to their corresponding monomers. Multimeric ligands may provide opportunities in the field of drug discovery by providing enhanced selectivity and affinity of binding interactions, thus providing molecular-based targeted therapies. However, gaps in our knowledge currently exist regarding the quantitative measures for important design characteristics, such as flexibility, length and orientation of the inter-ligand linkers, receptor density and ligand sequence. In this review, multimeric ligand binding in two separate phases is examined. The prerecruitment phase describes the binding of one ligand of a multimer to its corresponding receptor, an event similar to monomeric ligand binding. This results in transient increases in the local concentration of the other ligands, leading to apparent cooperativity. The postrecruitment phase only occurs once all receptors have been aligned and bound by their corresponding ligand. This phase is analogous to DNA–DNA interactions in that the stability of the complex is derived from physical orientation. Multiple factors influence the kinetics and thermodynamics of multimeric binding, and these are discussed.

[1]  P. Conn,et al.  Potency enhancement of a GnRH agonist: GnRH-receptor microaggregation stimulates gonadotropin release. , 1982, Endocrinology.

[2]  R. Bittman,et al.  Inhibition of protein kinase C(alpha) by dequalinium analogues: dependence on linker length and geometry. , 2000, Journal of medicinal chemistry.

[3]  U. Marx,et al.  The structure of human parathyroid hormone‐related protein(1–34) in near‐physiological solution , 1999, FEBS letters.

[4]  T. L. Blundell,et al.  The relation of polypeptide hormone structure and flexibility to receptor binding: The relevance of X-ray studies on insulins, glucagon and human placental lactogen , 1975, Molecular and Cellular Biochemistry.

[5]  K. Sakaguchi,et al.  Dimerization of neurokinin A and B COOH-terminal heptapeptide fragments enhanced the selectivity for tachykinin receptor subtypes. , 1988, European journal of pharmacology.

[6]  J. F. Stoddart,et al.  Probing polyvalency in artificial systems exhibiting molecular recognition. , 2002, The Journal of organic chemistry.

[7]  V. Seredyuk,et al.  Bolaforms with fourteen galactose units: a proposed site-directed cohesion of cancer cells. , 2004, Organic letters.

[8]  B. Pullman,et al.  The electronic structure of the purine-pyrimidine pairs of DNA. , 1959, Biochimica et biophysica acta.

[9]  G M Whitesides,et al.  A trivalent system from vancomycin.D-ala-D-Ala with higher affinity than avidin.biotin. , 1998, Science.

[10]  R. Mattson,et al.  Bivalent indoles exhibiting serotonergic binding affinity , 1995 .

[11]  B. Baird,et al.  Highly effective poly(ethylene glycol) architectures for specific inhibition of immune receptor activation. , 2003, Biochemistry.

[12]  M. Shive,et al.  Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[13]  W. Hol,et al.  High-Affinity Pentavalent Ligands of Escherichia coli Heat-Labile Enterotoxin by Modular Structure-Based Design , 2000 .

[14]  R. Schwyzer,et al.  Tobacco mosaic virus-enkephalin conjugates: Potentiation of opioid activity , 1981, Peptides.

[15]  L. Tan,et al.  Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[16]  G. Whitesides,et al.  Nonstatistical binding of a protein to clustered carbohydrates. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. L. Larson,et al.  Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors. , 1996, Journal of medicinal chemistry.

[18]  E. Whalley,et al.  A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. , 1992, Journal of medicinal chemistry.

[19]  R. Gaspar,et al.  A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. , 2001, Biochimica et biophysica acta.

[20]  I. Tinoco,et al.  The stability of helical polynucleotides: base contributions. , 1962, Journal of molecular biology.

[21]  R. Gillies,et al.  Expression-driven reverse engineering of targeted imaging and therapeutic agents , 2003, Expert opinion on therapeutic targets.

[22]  D. L. Larson,et al.  Opioid agonist and antagonist bivalent ligands as receptor probes. , 1982, Life sciences.

[23]  H. Blöcker,et al.  Predicting DNA duplex stability from the base sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G Poste,et al.  Measurement of the lateral mobility of cell surface components in single, living cells by fluorescence recovery after photobleaching. , 1976, Journal of supramolecular structure.

[25]  D. Cram,et al.  Host-Guest Chemistry: Complexes between organic compounds simulate the substrate selectivity of enzymes. , 1974, Science.

[26]  M. Mrksich,et al.  Model Systems for Studying Polyvalent Carbohydrate Binding Interactions , 2002 .

[27]  M. Lerner,et al.  Synthesis and characterization of bivalent peptide ligands targeted to G-protein-coupled receptors. , 1996, Chemistry & biology.

[28]  W. Bode,et al.  Bivalent inhibition of human beta-tryptase. , 2001, Chemistry & biology.

[29]  R. Grubbs,et al.  Inhibition of cell adhesion to fibronectin by oligopeptide-substituted polynorbornenes. , 2001, Journal of the American Chemical Society.

[30]  Ji Young Kim,et al.  Multivalent Inhibition of AB5 Toxins , 2001 .

[31]  J. Wetmur DNA probes: applications of the principles of nucleic acid hybridization. , 1991, Critical reviews in biochemistry and molecular biology.

[32]  P. Portoghese,et al.  Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites , 1982 .

[33]  R L Juliano,et al.  (Arg-Gly-Asp)n-albumin conjugates as a model substratum for integrin-mediated cell adhesion. , 1989, Experimental cell research.

[34]  R. Schiffelers,et al.  Peptide-targeted PEG-liposomes in anti-angiogenic therapy. , 2003, International journal of pharmaceutics.

[35]  A. Plückthun,et al.  New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.

[36]  V. Hruby,et al.  Conformational and dynamic considerations in peptide structure-function studies , 1982, Peptides.

[37]  L. Kiessling,et al.  Chapter 29. Principles for multivalent ligand design , 2000 .

[38]  J. Wetmur Hybridization and renaturation kinetics of nucleic acids. , 1976, Annual review of biophysics and bioengineering.

[39]  Watt W. Webb,et al.  Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension , 2003, Nature.

[40]  V. Hruby,et al.  Human epidermal melanocyte and keratinocyte melanotropin receptors: visualization by melanotropic peptide conjugated macrospheres (polyamide beads) , 1997, Experimental dermatology.

[41]  F. Lemonnier,et al.  A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. , 2003, Vaccine.

[42]  R. Standaert,et al.  Chemically induced dimerization of dihydrofolate reductase by a homobifunctional dimer of methotrexate. , 2000, Chemistry & biology.

[43]  R. Liskamp,et al.  Amino propynyl benzoic acid building block in rigid spacers of divalent ligands binding to the Syk SH2 domains with equally high affinity as the natural ligand. , 2003, Bioorganic & medicinal chemistry letters.

[44]  M. Germann,et al.  Design of Peptides with High Affinities for Heparin and Endothelial Cell Proteoglycans* , 2000, The Journal of Biological Chemistry.

[45]  Jason E Gestwicki,et al.  Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. , 2002, Journal of the American Chemical Society.

[46]  S. Das,et al.  Binding of multivalent carbohydrates to concanavalin A and Dioclea grandiflora lectin. Thermodynamic analysis of the "multivalency effect". , 2000, The Journal of biological chemistry.

[47]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[48]  D M Crothers,et al.  The influence of polyvalency on the binding properties of antibodies. , 1972, Immunochemistry.

[49]  J. Changeux,et al.  Allosteric proteins and cellular control systems. , 1963, Journal of molecular biology.

[50]  S Cusack,et al.  Kinetic Analysis of Adenovirus Fiber Binding to Its Receptor Reveals an Avidity Mechanism for Trimeric Receptor-Ligand Interactions* , 2001, The Journal of Biological Chemistry.

[51]  R. Britten,et al.  Repeated sequences in DNA. Hundreds of thousands of copies of DNA sequences have been incorporated into the genomes of higher organisms. , 1968, Science.

[52]  K. M. Parkhurst,et al.  Kinetic studies by fluorescence resonance energy transfer employing a double-labeled oligonucleotide: hybridization to the oligonucleotide complement and to single-stranded DNA. , 1995, Biochemistry.

[53]  Deborah L. Higgins,et al.  Multivalent drug design. Synthesis and in vitro analysis of an array of vancomycin dimers. , 2003, Journal of the American Chemical Society.

[54]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[55]  R. Schwyzer,et al.  Tobacco mosaic virus as a carrier for small molecules: Artificial receptor antibodies and superhormones , 1981, Biopolymers.

[56]  R. Huber,et al.  Synthesis of bivalent inhibitors of eucaryotic proteasomes , 2000, Journal of peptide science : an official publication of the European Peptide Society.

[57]  V. Hruby,et al.  Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. M. Riley,et al.  Dimers of D-myo-inositol 1,4,5-trisphosphate: design, synthesis, and interaction with Ins(1,4,5)P3 receptors. , 2004, Bioconjugate chemistry.

[59]  A. M. Riley,et al.  Interactions of Inositol 1,4,5-Trisphosphate (IP3) Receptors with Synthetic Poly(ethylene glycol)-linked Dimers of IP3 Suggest Close Spacing of the IP3-binding Sites* , 2002, The Journal of Biological Chemistry.

[60]  Jean-Luc Coll,et al.  Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. , 2004, Journal of the American Chemical Society.

[61]  Jason E Gestwicki,et al.  Control of multivalent interactions by binding epitope density. , 2002, Journal of the American Chemical Society.

[62]  V. Hruby,et al.  Multivalent melanotropic peptide and fluorescent macromolecular conjugates: new reagents for characterization of melanotropin receptors. , 1994, Bioconjugate chemistry.

[63]  E. Toone,et al.  The cluster glycoside effect. , 2002, Chemical reviews.

[64]  Hong Qian,et al.  Nanometre-level analysis demonstrates that lipid flow does not drive membrane glycoprotein movements , 1989, Nature.

[65]  J. Sridhar,et al.  New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. , 2003, Journal of medicinal chemistry.

[66]  P. Pauwels,et al.  Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. , 1998, Bioorganic & medicinal chemistry letters.

[67]  N. Gates,et al.  Kinetics of Renaturation of DNA , 2003 .

[68]  G. Boons,et al.  High-avidity, low-affinity multivalent interactions and the block to polyspermy in Xenopus laevis. , 2002, Journal of the American Chemical Society.

[69]  R. Kramer,et al.  Spanning binding sites on allosteric proteins with polymer-linked ligand dimers , 1998, Nature.

[70]  K. Jacobson,et al.  New insights into membrane dynamics from the analysis of cell surface interactions by physical methods. , 1995, Current opinion in cell biology.

[71]  W. Bode,et al.  Bivalent inhibition of human β-tryptase , 2001 .

[72]  L. Kiessling,et al.  Synthetic multivalent ligands in the exploration of cell-surface interactions. , 2000, Current opinion in chemical biology.

[73]  P. Carlier,et al.  Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities. , 1999, Bioorganic & medicinal chemistry.

[74]  Y. C. Lee,et al.  Neoglycoconjugates : preparation and applications , 1994 .

[75]  R. Rownd,et al.  Denaturation and Renaturation of Deoxyribonucleic Acid12 , 1963 .

[76]  H R Hoogenboom,et al.  Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.

[77]  J. Stewart,et al.  Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  A Kusumi,et al.  Compartmentalized structure of the plasma membrane for receptor movements as revealed by a nanometer-level motion analysis , 1994, The Journal of cell biology.

[79]  Randy J. Read,et al.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands , 2000, Nature.

[80]  George M Whitesides,et al.  Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.

[81]  V. Hruby,et al.  Human epidermal melanocyte and keratinocyte melanocortin receptors: visualization by melanotropic peptide conjugated microspheres (latex beads). , 1996, Pigment cell research.

[82]  H. Kodama,et al.  Dimeric chemotactic peptides discriminate between chemotaxis and superoxide production of human neutrophils. , 1995, Journal of biochemistry.

[83]  M Baba,et al.  Structure-activity relationship studies with symmetric naphthalenesulfonic acid derivatives. Synthesis and influence of spacer and naphthalenesulfonic acid moiety on anti-HIV-1 activity. , 1993, Journal of medicinal chemistry.

[84]  Robert J Gillies,et al.  Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. , 2004, Bioorganic & medicinal chemistry letters.

[85]  W. Atkins,et al.  Novel class of bivalent glutathione S-transferase inhibitors. , 2003, Biochemistry.

[86]  C. Verlinde,et al.  Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin. , 2002, Journal of the American Chemical Society.

[87]  C. Hill,et al.  Stoichiometry of Active Smad-Transcription Factor Complexes on DNA* , 2002, The Journal of Biological Chemistry.

[88]  M. Matrosovich Towards the development of antimicrobial drugs acting by inhibition of pathogen attachment to host cells: A need for polyvalency , 1989, FEBS letters.

[89]  P. Pauwels,et al.  Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists. , 1996, Journal of medicinal chemistry.

[90]  G. Whitesides,et al.  A trivalent system from vancomycin center dot D-Ala-D-Ala with higher affinity than avidin center dot biotin , 1998 .

[91]  D. Acheson,et al.  Multivalent inhibition of AB(5) toxins. , 2001, Journal of the American Chemical Society.

[92]  R. Huber,et al.  Bivalency as a principle for proteasome inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[93]  L. Kiessling,et al.  Tuning chemotactic responses with synthetic multivalent ligands. , 2000, Chemistry & biology.

[94]  S. Yabuki,et al.  [Denaturation and renaturation of deoxyribonucleic acids (author's transl)]. , 1973, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[95]  David M. Gooden,et al.  Additivity and the physical basis of multivalency effects: a thermodynamic investigation of the calcium EDTA interaction. , 2003, Journal of the American Chemical Society.

[96]  R. Britten,et al.  Repeated Sequences in DNA , 1968 .

[97]  C Boesch,et al.  1H nuclear-magnetic-resonance studies of the molecular conformation of monomeric glucagon in aqueous solution. , 1978, European journal of biochemistry.

[98]  T. Griffin,et al.  An approach to predicting the stabilities of peptide nucleic acid:DNA duplexes. , 1998, Analytical biochemistry.

[99]  J. Casasnovas,et al.  Kinetics and Thermodynamics of Virus Binding to Receptor. , 1995, The Journal of Biological Chemistry.